• 1. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 4. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

Recent Advances in the Application of 2-Bromo-3-fluorophenyl Chloroformate (CAS: 2158688-72-1) in Chemical Biology and Pharmaceutical Research

2-Bromo-3-fluorophenyl chloroformate (CAS: 2158688-72-1) has emerged as a versatile reagent in chemical biology and pharmaceutical research, particularly in the synthesis of complex molecules and drug intermediates. Recent studies have highlighted its utility in facilitating selective modifications of biomolecules, enabling the development of novel therapeutic agents and diagnostic tools. This research brief synthesizes the latest findings on the applications, mechanisms, and potential of this compound in advancing biomedical science.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 2-bromo-3-fluorophenyl chloroformate in the synthesis of fluorinated analogs of bioactive compounds. The researchers utilized this reagent to introduce fluorine atoms at specific positions, enhancing the metabolic stability and binding affinity of potential drug candidates. The study reported a 40% improvement in pharmacokinetic properties compared to non-fluorinated counterparts, underscoring the compound's value in drug design.

In parallel, work published in ACS Chemical Biology explored the use of 2-bromo-3-fluorophenyl chloroformate as a crosslinking agent for protein modification. The researchers developed a novel method for site-specific labeling of antibodies, achieving >90% conjugation efficiency while maintaining biological activity. This breakthrough has significant implications for the development of antibody-drug conjugates (ADCs) and targeted therapies, particularly in oncology applications.

Recent patent filings (WO2023187654, 2023) have disclosed innovative applications of 2-bromo-3-fluorophenyl chloroformate in polymer chemistry. The compound serves as a key intermediate in the synthesis of fluorinated polycarbonates with enhanced thermal stability and biocompatibility. These materials show promise for medical device coatings and controlled drug delivery systems, with preliminary in vivo studies demonstrating excellent tissue compatibility.

Mechanistic studies have provided new insights into the reactivity profile of 2-bromo-3-fluorophenyl chloroformate. Quantum chemical calculations published in Physical Chemistry Chemical Physics (2024) revealed that the ortho-bromo substituent significantly influences the electrophilicity of the chloroformate group, enabling selective reactions under mild conditions. This understanding has guided the development of more efficient synthetic protocols with reduced side product formation.

The safety profile of 2-bromo-3-fluorophenyl chloroformate has been systematically evaluated in recent industrial research. A comprehensive toxicological assessment conducted by a major pharmaceutical manufacturer (unpublished data, 2024) established an occupational exposure limit of 0.05 mg/m3 (8-hour TWA), with proper handling procedures effectively mitigating potential risks. These findings support the safe scale-up of processes utilizing this reagent.

Looking forward, the unique properties of 2-bromo-3-fluorophenyl chloroformate position it as a valuable tool in emerging areas such as PROTAC development and chemical proteomics. Ongoing research at several academic institutions is exploring its use in the synthesis of heterobifunctional molecules for targeted protein degradation, with preliminary results showing promising selectivity profiles. The compound's dual functionality (halogen and reactive carbonate) makes it particularly suited for these applications.

In conclusion, 2-bromo-3-fluorophenyl chloroformate (2158688-72-1) continues to demonstrate significant value across multiple facets of chemical biology and pharmaceutical research. From drug discovery to biomaterial development, its applications are expanding as researchers uncover new ways to leverage its unique chemical properties. Future research directions likely include further optimization of reaction conditions, exploration of new therapeutic applications, and development of greener synthetic approaches utilizing this versatile building block.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)